secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2023-11-20T23:59:59+00:00
Accession:  0001193125-23-280283
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio's INB-200 Phase 1 trial: all patients completing doses exceed 7-month PFS; one remains alive at 28.5+ months
--------------------------------------------------------------------------------

- All ten patients who completed mandated doses exceeded progression-free survival (PFS) of 7 months, exceeding standard-of-care median PFS of 4-7 months.
- One patient with IDH-mutant glioma remains alive and progression-free at 28.5+ months (median PFS for IDH-mutant patients in NEJM control arm: 11.1 months).
- No treatment-related serious adverse events, dose-limiting toxicities, cytokine release syndrome, infusion reactions, or ICANS reported.
- Three dosing cohorts: Cohort 1 (1 dose, 3 pts), Cohort 2 (3 doses, 4 pts), Cohort 3 (6 doses, 3 pts); additional enrollment in Cohort 3 expected to complete in 2023.
- Preserved gamma-delta T cells found in relapsed tumor 148 days after initial DRI infusion, indicating durability of cells.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523280283/0001193125-23-280283-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312523280283/d900996d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-280283

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer